Alnylam Pharmaceuticals
ALNY
#572
Rank
โ‚น3.852 T
Marketcap
โ‚น29,052
Share price
-1.18%
Change (1 day)
32.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024: -โ‚น22 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น3.21 Billion. In 2024 the company made an earning of -โ‚น22 Billion, an increase over its 2023 earnings that were of -โ‚น29.17 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024-โ‚น22 Billion-24.59%
2023-โ‚น29.17 Billion-67.84%
2022-โ‚น90.68 Billion36.93%
2021-โ‚น66.23 Billion-8.04%
2020-โ‚น72.01 Billion-15.66%
2019-โ‚น85.39 Billion12.23%
2018-โ‚น76.08 Billion62.91%
2017-โ‚น46.71 Billion17.78%
2016-โ‚น39.66 Billion43.44%
2015-โ‚น27.65 Billion60.69%
2014-โ‚น17.21 Billion98.2%
2013-โ‚น8.68 Billion
2011-โ‚น5.12 Billion27.48%
2010-โ‚น4.02 Billion-10.92%
2009-โ‚น4.51 Billion95.77%
2008-โ‚น2.31 Billion
2006-โ‚น3.69 Billion-9.13%
2005-โ‚น4.06 Billion34.74%
2004-โ‚น3.02 Billion36.79%
2003-โ‚น2.21 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
โ‚น1.527 T 12,447.77%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น849.82 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
โ‚น488.46 B 3,913.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น23.56 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น4.43 Billion-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น14.9 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
โ‚น200.96 B 1,551.35%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
โ‚น13.15 B 8.12%๐Ÿ‡บ๐Ÿ‡ธ USA